Arthritis, Psoriatic
90
12
19
54
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
28 trials with published results (31%)
Research Maturity
54 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.7%
6 terminated out of 90 trials
90.0%
+3.5% vs benchmark
32%
29 trials in Phase 3/4
52%
28 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (90)
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Pain in Inflammatory Joint Diseases
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
A Long-term Extension Study of Ustekinumab in Pediatric Participants
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases